Erasca (ERAS)
Develops pan-RAS and pan-KRAS therapies for RAS/MAPK-driven solid tumors.
Something off on this page? Send us feedback.
Develops clinical-stage precision oncology drugs for RAS/MAPK-driven cancers, led by pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001. With no approved products or product revenue, operations depend on clinical results, regulatory approval, external licenses, manufacturers, and financing.
Develops precision oncology therapies aimed at cancers driven by the RAS/MAPK signaling pathway. The clinical pipeline centers on ERAS-0015, a pan-RAS molecular glue tested alone and with other cancer medicines, and ERAS-4001, a pan-KRAS inhibitor; both are in Phase 1 trials for RAS- or KRAS-mutant solid tumors. ERAS-12, an EGFR-targeting antibody, remains in discovery.
Concentrates resources on the RAS franchise after ending development of naporafenib, and advances programs through trials in the United States while its ERAS-0015 licensor conducts a separate study in China. No product is approved and the business has generated no product revenue. Progress depends on clinical results, regulatory clearance, continued financing, third-party trial and manufacturing providers, and licenses covering its two clinical candidates.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Guggenheim | Reiterate | Rating: —Target: $12 | Target: $21 |
| Aug 12, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $22 |
| Jul 20, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $10 | Target: $21 |
| Jul 14, 2026 | Jefferies | Reiterate | Rating: —Target: $6 | Target: $24 |
| Jul 14, 2026 | HSBC | Target | Target: — | Target: $20 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $268.7M · Total debt $44.7M · Total assets $435.1M · Shareholders' equity $361.9M
- Revenue
- $0
- Operating income
- −$47.6M
- Net income
- −$44.1M
No dividends on record.
| Institutions | ≈ 79.08% | 276.59M shares | |
|---|---|---|---|
| 274 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.14% | 477.9K shares | |
| 3 holders · as of Apr 3, 2026 | |||
| Other | ≈ 20.78% | 72.70M shares | |
| remainder | |||
349.76M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Frazier Life Sciences Management, L.P.Institution | 7.14% | 24.98M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 6.06% | 21.19M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.05% | 21.15M | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 5.13% | 17.95M | as of Jun 30, 2026 |
VR Adviser, LLCInstitution | 5.12% | 17.89M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 1, 2026 | Ebun Garner | officer: Chief Legal Officer | −80,000 | $16.40 |
| Mar 4, 2026 | Shannon Morris | officer: Chief Medical Officer | −20,000 | $15.04 |
| Jan 7, 2026 | Ebun Garner | officer: General Counsel & Corp. Sec. | −120,000 | $5.59 |
- Revolution Medicines
Late-stage RAS(ON) inhibitor portfolio with pivotal Phase 3 data in PDAC
- Amgen
First approved KRAS G12C franchise; sotorasib in NSCLC and mCRC combos
- Bristol-Myers Squibb
Adagrasib (KRAZATI) approved for KRAS G12C NSCLC and CRC; Phase 3 ongoing
- Eli Lilly
Phase 3 KRAS G12C (olomorasib) plus pan-KRAS and G12D inhibitors in Phase 1
- Verastem
Dual RAF/MEK inhibitor approved in LGSOC; KRAS G12D inhibitor in Phase 2 trials
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Erasca | $15.55 | +0.03% | $5.22B | — | — | — | — |
| Revolution Medicines | $193.07 | 0.00% | $40.98B | — | — | — | — |
| Amgen | $410.04 | −0.04% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Bristol-Myers Squibb | $62.25 | +0.01% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Eli Lilly | $1,171.64 | +0.10% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Verastem | $8.37 | −0.12% | $702.1M | — | — | 8.0 | +1,775.4% |
| Median | 24.4 | 17.5 | 6.8 | +28.7% |